HNF1B and ovarian clear cell cancer: The prognosis for ovarian clear cell carcinoma (CCC) patients with advanced‐stage disease is poor owing to intrinsic resistance to platinum‐based chemotherapy and the lack of targeted therapies available.1 Overexpression of the hepatocyte nuclear factor 1β (HNF1β) transcription factor is the most important clinical immunohistochemical marker for the disease, since it is ubiquitously overexpressed in CCC.2 However, to date, drugs targeting HNF1β have not been developed due to the high content of intrinsically disordered regions in transcription factors.3